Share on StockTwits

Analysts at Dougherty & Co began coverage on shares of Gen-Probe (NASDAQ:GPRO) in a research report issued to clients and investors on Wednesday. The firm set a “buy” rating on the stock.

The stock’s 50-day moving average is $0. and its 200-day moving average is $0..

Gen-Probe Incorporated (NASDAQ:GPRO) is engaged in the development, manufacture and marketing molecular diagnostic products and services, which are used primarily to diagnose human diseases, screen donated human blood, and ensures transplant compatibility.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.